Jeffrey Carr, MD
Interventional Cardiology · Tyler, TXNPI 1649260373
Payments from drug & device makers
What this record shows
This record is dominated by other: $1,497,691 of the $1,886,393 with a category attached, or 79.4%. Bard Peripheral Vascular, Inc. accounts for 85.9% of it on its own, with 51 other manufacturers making up the rest. Reporting peaked in 2021 at $1,515,800 and has fallen 99.0% since, to $15,827 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $3344.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$1.6M
- Medtronic$121K
- Philips North America LLC$62K
- Venclose Inc.$38K
- Abbott$22K
- Cordis US CORP.$6K
- plus $17K from 46 others
Across 533 payments — averaging $1548.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$541K
- Bard Peripheral Vascular, Inc.$134K
- Novartis$70K
- Philips North America LLC$30K
- Bayer$22K
- Abbott$12K
- plus $16K from 3 others
What the payments were for
- Royalty or licence$57,1343%
- Consulting fees$203,51511%
- Speaking & faculty fees$90,6995%
- Travel & lodging$19,6891%
- Food & beverage$17,6631%
- Education$20%
- Other$1,497,69179%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$60,334
- Venclose$38,000
- IGT D Peripheral$29,991
- Spectranetics Undiv$22,374
- Omnilink Elite vascular stent system$14,048
- IN.PACT Admiral$13,007
- HawkOne$12,377
- ClosureFast$11,800
- (9520) IGT Devices Undivided$6,100
- FlowMet$6,000
- Product in Development$4,275
- MYNX CONTROL VENOUS$3,001
- TurboHawk$2,982
- Supera peripheral stent system$2,750
- SUPERA$2,250
- BRITE TIP$2,250
- VENOVO$2,079
- Tack Endovascular System$2,000
- EverCross$1,313
- Endurant$924
How this compares
$1,886,393 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 120 | $126,020 |
| EliquisApixaban | 101 | $80,206 |
| EntrestoSacubitril/Valsartan | 57 | $61,500 |
| BrilintaTicagrelor | 39 | $32,013 |
| Praluent PenAlirocumab | 17 | $10,923 |
| Repatha SureclickEvolocumab | 11 | $9,199 |
| JardianceEmpagliflozin | 14 | $8,891 |
| Metoprolol Succinate | 318 | $6,300 |
| Rosuvastatin Calcium | 173 | $3,173 |
| Nebivolol Hcl | 46 | $3,059 |
| Cilostazol | 138 | $2,780 |
| ClopidogrelClopidogrel Bisulfate | 239 | $2,678 |
| Torsemide | 106 | $2,501 |
| Ranolazine ErRanolazine | 28 | $2,369 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 202 | $1,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $723 | $126,020120 claims |
| PfizerEliquis | $13 | $80,206101 claims |
| NovartisEntresto | $399 | $61,50057 claims |
| AstraZenecaBrilinta | $54 | $32,01339 claims |
| Boehringer IngelheimJardiance | $70 | $8,89114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Tyler
- Preetham Reddy MuskulaTyler$91K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.